Document is current
Any future updates will be listed below
-
Authors
Iazzolino, Barbara
Grassano, Maurizio
Moglia, Cristina
Canosa, Antonio
Manera, Umberto
Vasta, Rosario
Cabras, Sara
Callegaro, Stefano
Matteoni, Enrico
Di Pede, Francesca
Palumbo, Francesca
Mora, Gabriele
Calvo, Andrea
Chiò, Adriano https://orcid.org/0000-0001-9579-5341
-
Funding
Funding for this research was provided by:
Ministero della Salute (RF-2016-02362405)
Ministero dell’Istruzione, dell’Università e della Ricerca (2017SNW5MB)
Seventh Framework Programme (259867)
Horizon 2020 Framework Programme (101017598)
- License Information
-
More Information
Article History
Received: 5 September 2023
Revised: 8 October 2023
Accepted: 9 October 2023
First Online: 25 October 2023
Declarations
:
: Adriano Chiò serves on scientific advisory boards for Mitsubishi Tanabe, Biogen, Roche, Denali Pharma, Cytokinetics, Lilly, Ferrer, Zambon Biotech, and Amylyx Pharmaceuticals and has received a research grant from Biogen. Barbara Iazzolino, Maurizio Grassano, Cristina Moglia, Antonio Canosa, Umberto Manera, Rosario Vasta, Sara Cabras, Stefano Callegaro, Enrico Matteoni, Francesca Di Pede, Francesca Palumbo, Gabriele Mora have no disclosures. Andrea Calvo has received a research grant from Cytokinetics.
: Standard Protocol Approvals, Registrations, and Patient Consents. The study was approved by the Ethics Committees of the ALS Expert Center of Torino (Comitato Etico Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, #0038876). Patients and controls provided written informed consent before enrollment. The databases were anonymized according to Italian law for the protection of privacy.
